EICHOR
● Completed
Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
Condition: Advanced/Metastatic Cervical Cancer · Sponsor: Centre Francois Baclesse
About this study
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (8)
| Institut de cancérologie de l'Ouest | Angers, France | — |
| Centre François Baclesse | Caen, France | — |
| Centre Oscar LAMBRET | Lille, France | — |
| Centre Léon Bérard | Lyon, France | — |
| Institut de Cancérologie de Montpellier | Montpellier, France | — |
| Institut de cancérologie de l'Ouest | Nantes, France | — |
| Institut CURIE | Saint-Cloud, France | — |
| Institut Gustave Roussy | Villejuif, France | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.